RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+12.64%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$3.53B
AUM Growth
+$116M
Cap. Flow
-$73.8M
Cap. Flow %
-2.09%
Top 10 Hldgs %
47.92%
Holding
99
New
17
Increased
28
Reduced
21
Closed
18
Avg Time Held Equity + Options
1.4 years
Top 10 Avg Time Held Equity + Options
1.3 years
Top 20 Avg Time Held Equity + Options
1.4 years
Avg Time Held Equity only
1.4 years
Top 10 Avg Time Held Equity only
1.3 years
Top 20 Avg Time Held Equity only
1.4 years

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$51.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$50.1M
3
FOLD icon
Amicus Therapeutics
FOLD
+$40.3M
4
CNC icon
Centene
CNC
+$37.3M
5
STOK icon
Stoke Therapeutics
STOK
+$27.4M

Top Sells

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$82.5M
2
ARRY icon
Array Biopharma Inc
ARRY
+$62.3M
3
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$49.3M
4
PEN icon
Penumbra
PEN
+$47.5M
5
XNCR icon
Xencor
XNCR
+$46.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.51%
2 Miscellaneous 2.32%
3 Financials 2.17%
4 Energy 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CNC icon
26
Centene
CNC
$34.5B
$36.2M 1.03%
+690,870
New +$37.3M
2019 Q2
0 quarters
GRTS icon
27
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$35.8M 1.01%
3,215,994
+862,259
+37% +$9.86M
2018 Q3
3 quarters
UNH icon
28
UnitedHealth
UNH
$353B
$34.6M 0.98%
141,901
+9,011
+7% +$2.17M
2016 Q3
11 quarters
ANAB icon
29
AnaptysBio
ANAB
$1.39B
$34.4M 0.97%
609,658
+112,740
+23% +$8.12M
2017 Q4
6 quarters
XERS icon
30
Xeris Biopharma Holdings
XERS
$1.81B
$34.3M 0.97%
3,000,641
– –
2018 Q2
4 quarters
SYRS icon
31
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$33.5M 0.95%
362,038
+197,518
+120% +$13.8M
2016 Q2
12 quarters
AXNX icon
32
DELISTED
Axonics, Inc. Common Stock
AXNX
$33.3M 0.94%
813,500
+214,900
+36% +$6.04M
2018 Q4
2 quarters
REPL icon
33
Replimune Group
REPL
$1.1B
$32.2M 0.91%
2,197,003
-15,453
-0.7% -$223K
2018 Q3
3 quarters
TDOC icon
34
Teladoc Health
TDOC
$1.04B
$30.7M 0.87%
461,880
+21,980
+5% +$1.28M
2017 Q4
6 quarters
LIVN icon
35
LivaNova
LIVN
$4.18B
$30.5M 0.86%
423,987
-158,700
-27% -$11.6M
2017 Q2
8 quarters
IMGN icon
36
DELISTED
Immunogen Inc
IMGN
$30.3M 0.86%
13,954,794
+891,027
+7% +$2.11M
2017 Q1
9 quarters
STOK icon
37
Stoke Therapeutics
STOK
$1.49B
$29.8M 0.84%
+1,021,808
New +$27.4M
2019 Q2
0 quarters
EIDX
38
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$27.3M 0.77%
878,403
+26,503
+3% +$718K
2018 Q2
4 quarters
ODT
39
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$27.2M 0.77%
740,671
+263,207
+55% +$6.31M
2017 Q4
6 quarters
DXCM icon
40
DexCom
DXCM
$31.7B
$25.8M 0.73%
+688,400
New +$21.6M
2019 Q2
0 quarters
TCRR
41
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$25.7M 0.73%
1,799,216
-8,040
-0.4% -$128K
2019 Q1
1 quarter
OXFD
42
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$24.7M 0.7%
1,796,477
-204,990
-10% -$3.14M
2013 Q4
22 quarters
JAZZ icon
43
Jazz Pharmaceuticals
JAZZ
$13.7B
$24M 0.68%
168,387
-101,093
-38% -$13.6M
2018 Q2
4 quarters
CBIO icon
44
Crescent Biopharma
CBIO
$469M
$23.9M 0.68%
20,084
-98
-0.5% -$117K
2017 Q2
8 quarters
CBAY icon
45
DELISTED
Cymabay Therapeutics
CBAY
$22.5M 0.64%
3,138,365
+194,600
+7% +$2.2M
2017 Q3
7 quarters
AKRO icon
46
DELISTED
Akero Therapeutics
AKRO
$22.4M 0.63%
+1,168,802
New +$22.2M
2019 Q2
0 quarters
VAPO
47
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$22.1M 0.62%
119,942
-6,473
-5% -$958K
2018 Q4
2 quarters
BCEL
48
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$21.5M 0.61%
+1,140,306
New +$20.6M
2019 Q2
0 quarters
ADPT icon
49
Adaptive Biotechnologies
ADPT
$4.1B
$20.5M 0.58%
+425,000
New +$18.8M
2019 Q2
0 quarters
MOR icon
50
DELISTED
MorphoSys AG American Depositary Shares
MOR
$17.7M 0.5%
733,699
-160,101
-18% -$3.97M
2018 Q2
4 quarters
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2019 Portfolio in Review

As of Q2 2019, Redmile Group held 99 positions worth $3.53B, up 3.4% from $3.42B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group's Q2 2019 filing shows 17 new, 28 increased, 21 reduced and 18 closed positions. Its largest new stake was Sarepta Therapeutics: 412,000 shares worth $62.6M. The largest sale was InflaRx, an estimated $82.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Miscellaneous and Financials.

  • Redmile Group's largest Q2 2019 buy was Sarepta Therapeutics: 412,000 shares worth $62.6M.
  • Redmile Group added most to Tricida, Inc. Common Stock in Q2 2019, an estimated $51.2M increase.
  • Redmile Group's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $62.3M.
  • Redmile Group fully exited InflaRx in Q2 2019, selling an estimated $82.5M.
  • Redmile Group's ten largest holdings make up 48% of its $3.53B portfolio in Q2 2019.
  • Redmile Group opened 17 new positions and closed 18 in Q2 2019.
  • Redmile Group's portfolio value rose 3.4% quarter-over-quarter to $3.53B.

Based on Redmile Group's 13F filing for Q2 2019, filed 14 Aug 2019.